UK based Altair Medical today announced, as part of its ongoing growth story, that it is rebranding to PneumoWave. The name fully reflects the digital therapeutics platform that the company believes will transform respiratory healthcare. In a key step towards commercial launch of the platform, a multi-centre program of clinical trials is currently underway in leading academic and healthcare institutions.

Altair Medical was founded in 2018 with the purpose of developing remote monitoring technology for patients with acute and chronic respiratory conditions. The platform will provide patients, clinicians and researchers with real-time physiological data and patient centric biomarkers to predict, monitor and alert to respiratory adverse events in hospitals and at home.

Having been identified as a device offering significant advantages over existing approved or cleared alternatives, and being in the best interests of patients, PneumoWave has been awarded FDA (US Food & Drug Administration) Breakthrough Medical Device designation. 

Following market feedback and as the technology gets closer to commercial launch, the name PneumoWave was chosen to better reflect the ground-breaking work of the company. The Altair Medical name will no longer be used. 

Dr Bruce Henderson, PneumoWave CEO, comments, “We’ve reached the stage in our development where our growing team, clinical trial and leading academic partners know us as PneumoWave. The name reflects our core technology of remote respiratory monitoring, advanced algorithms and AI being used to diagnose underlying health events in real time. This allows those using the platform to provide therapeutic interventions and alerts to prevent unnecessary deaths and improve patient outcomes.” 

Jonathan Guthrie, PneumoWave Chairman, further explains, “Imminently we’re embarking on our next fund-raise and with commercial launch coming ever closer, we feel it’s time to bring clarity to the market with our new name. We’re excited to launch PneumoWave and are confident it will improve the medical outcomes of hundreds of thousands of people globally.”

“We thank our investors who backed us as Altair Medical through our £2.25m ($3.1m) Pre-Series A funding, and look forward to our next exciting growth period as PneumoWave.”